Genetic Preservation
Cannaflos Genetics, the Spanish subsidiary of Cannaflos, is active in the development of traceable cultivars of Cannabis sativa L..
The varieties offered by Cannaflos Genetics come from original landraces originating from different regions around the world, collected since 2009 through extensive research and development expeditions. Our cultivars are CPVO-registered and genetically traceable back to the landraces.
Map of origins
Cannaflos is proud and responsible owner of a unique germplasmbank of over 130 landraise genetics from 27 countries.
Map of origins
Together with TOMSBio Lab and the University of Valencia we conduct indepth research on Cannabis cultivars.
We have achieved:
- Chemical characterisation of the registered cultivars
- In vitro stabilisation of the registered cultivars
- Analysis to absence of pathogens of our registered cultivars
Our current research focus includes:
- Chemical analyses in Cannaflos’ lab (HPLC, GC-MS, NIR)
- NIR model for the prediction of metabolites
- Production of cuttings and seeds
- Breeding new cultivars
Together with IBB we conduct indepth research on the genetics of our spermoplasm bank and the corresponding cultivars.
We have achieved:
- Morphological characterisation of the registered cultivars
- Ensuring traceability and compliance with benefit-sharing agreements
Our current research focus includes:
- Evaluation (morphological and chemical characterisation) of 137 new landraces
Research Licenses
In order to conduct research on Cannabis genetics and cultivars, we obtained the necessary licenses:
AEMPS R&D and propagation license
AEMPS R&D license cultivation
Learn more about our ongoing research projects
Traditional Use of Cannabis
An in-depth investigation in the traditional use of the Cannabis plant and the and the diversity of landraised genetics
In search of premium quality mother plants, we conduct an ongoing phenohunt program through our network of authorised cultivation partners.
Get a deep understanding of the therapeutic application of Cannabis-based medication.
We aim to unlock precision medicine by capturing patient reported outcomes and driving point of care innovation.
Lorem ipsum dolor sit amet, consectetuer adipiscing elit. Lorem ipsum dolor sit amet, consectetuer adipiscing elit.
Licensed GDP-Wholesaler according to §52a AMG & §3 BtMG
Our innovative approach is promoted by
